MiNK Therapeutics Inc. Common Stock Q2 2026 Earnings Recap

Shares declined 0.8% following Q2 results as investors weighed early clinical progress against limited commercial traction and cautious near-term catalysts.

Key Takeaways

• Initiated randomized Phase 2 study of agenT-797 in acute lung injury and ARDS patients in Ukraine under challenging conditions.
• Early non-comparative data showed patients alive and fever-free at day 28 with signs of improved oxygenation and inflammation markers; however, data remain preliminary and require validation in ongoing randomized trial.
• No serious adverse events attributed to agenT-797, supporting initial safety profile.
• Launched first international named patient access program in Brazil, creating a paid, physician-directed pathway outside of clinical studies, but this is not a commercial launch.
• U.S. site activations for the Phase 2 trial are underway with additional clinical data expected in early 2027, leaving near-term inflection points limited.